mProX™ Human ADGRL4 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Smooth muscle cells and endothelial cells both express the orphan adhesion GPCR ADGRL4/ELTD1, which regulates both healthy and malignant angiogenesis. Zebrafish embryos with vascular abnormalities that were unable to support life were created when in vitro endothelium sprouting was blocked. ADGRL4/ELTD1 is overexpressed compared to the surrounding normal endothelium in tumor-associated endothelial cells from a variety of common tumor types (head and neck, renal, colorectal, ovarian, and brain malignancies), as well as from glioblastoma tumor cells. Systemic vascular ADGRL4/ELTD1 silencing lowered microvascular density and generated tumor shrinkage with improved survival in mice implanted with human tumor xenografts (colorectal and ovarian tumors). This was done without having a deleterious impact on the systemic vascular system. One explanation is that ADGRL4/ELTD1 may increase tumor drug administration by stabilizing blood vessels. Due to this, ADGRL4/ELTD1 is a important drug target. The customized ADGRL4 stable cell line can be employed in the signaling pathway researches, as well as the screening of potential therapeutic candidates.